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Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-
cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation
of autoreactive lymphocytes have been extensively studied in animal models of T1D, but remains ill deﬁned in man. In man, T
lymphocytes, especially CD8+ Tcells, are predominantwithin insulitis.Developing T-cell assays in diabetes autoimmunity is,thus,
amajorchallenge.Itisexpectedtohelpdeﬁningautoantigensandepitopesthatdrivethediseaseprocess,topinpointkeyfunctional
features of epitope-speciﬁc T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies
to induce immune tolerance to β-cells. New T-cell technologies will allow deﬁning autoreactive T-cell diﬀerentiation programs
and characterizing autoimmune responses in comparison with physiologically appropriate immune responses. This may prove
instrumental in the discovery of immune correlates of eﬃcacy in clinical trials.
1.Introduction
Type 1 diabetes (T1D) is an autoimmune disease driven
by the activation of lymphocytes against pancreatic β-cells.
While the successive steps that control the activation of
autoreactive lymphocytes have been extensively studied in
animal models, the disease process remains ill deﬁned in the
human[1].However,thepredominantroleofTlymphocytes
is characteristic of both mouse and human T1D. In the
mouse, T1D is transferred into naive recipients by T cells, is
prevented by antibodies that target T lymphocyte activation,
and fails to develop when key genes in T lymphocyte
diﬀerentiation or activation are non functional [2]. T1D is
a highly multigenic disease both in the mouse [3] and in the
human [4]. In man, T lymphocytes, especially CD8+ T cells,
are predominant within insulitis in most [5–11], although
not all [12], observations. Occurrence of T1D in a patient
deprived of B lymphocytes further underscores the role of T
lymphocytes [13].
Remarkable features in human T1D are the long pre-
clinical phase that precedes the development of full-blown
hyperglycemia [14] and the high recurrence level of autoim-
munity in long-standing patients who have been treated
with exogenous insulin for years [15]. The ﬁrst detection of
autoantibodies can occur at any time during life. However,
it peaks at one to three years of age in a large subset
of children who develop early T1D. A second incidence
peak is seen around puberty and show more heterogeneous
autoantibody proﬁles than in early forms of T1D [14]. Rapid
diabetes recurrence is seen in T1D recipients of an isograft
from a discordant, nondiabetic twin and is accompanied
by an almost exclusive CD8+ T-cell islet inﬁltration [15].
It, thus, seems that β-cell-speciﬁc T lymphocytes maintain
immune memory for years after T1D onset. However,
diﬀerentiation patterns of autoreactive T lymphocytes, once
diabetes diagnosed, remain largely unknown.
Amongβ-cellautoantigens(Table1),proinsulinhasbeen
ascribed a key role in the T1D process [1, 16]. In the NOD2 Clinical and Developmental Immunology
Table 1: Autoantigens deﬁned as recognized by T cells in human T1D. Listing has been limited to autoantigens for which evidence of
recognition has been obtained in the human or, if only in the mouse, data are expected in the human.
autoantigen expression Subcellular location Involvement in the NOD mouse
Human T1D
autoantibodies CD4+ Tc e l l s C D 8 + Tc e l l s
Insulin β-cell, thymus secretory granule + + + +
∗GAD 65 neuroendocrine synaptic-like
microvesicles ++ + +
GAD 67 neuroendocrine cytosol + + + +
IA-2 (ICA512) neuroendocrine secretory granule + + +
IA-2 β/phogrin neuroendocrine secretory granule + + +
IGRP β-cell endoplasmic
reticulum +? + +
Chromogranin neuroendocrine Secretory granule + ? ? ?
ZnT8 β-cell secretory granule ? + ? ?
HSP-60
HSP-70 ubiquitous mitochondria + + + ?
Glima-38 secretory granule ? + ? ?
Amylin/IAPP secretory granule ? ? ? +
CD38 ubiquitous ? ? ± ??
GAD: glutamate decarboxylase; IA-2: islet antigen 2; ZnT8; HSP: heat shock protein; IAPP; IGRP; ICA: islet cell antibody.
?: no positive results reported.
mouse, injection of insulin-speciﬁc T-cell clones accelerates
diabetes and protection is obtained by injecting insulin in
incomplete Freund’s adjuvant in prediabetic mice [2, 17].
Altered diabetes development in proinsulin 1−/− or 2−/−
NODmicemakesastrongcasefortheprimaryroleofinsulin
in this model [18–20]. By contrast, deﬁcient expression of
glutamate decarboxylase (GAD) or islet antigen 2 (IA-2)
has no striking eﬀect on diabetes development in this
model [21, 22]. Antigen spreading may thus explain the
activation of T cells against a long list of autoantigens once
the autoimmune process on. T cell clones that are speciﬁc
for GAD, chromogranin and islet-glucose-6-phosphatase
catalytic subunit-related protein (IGRP) are indeed detected
and transfer diabetes into naive NOD recipients [23–26].
In man, insulin and proinsulin are common targets of
autoantibodies and T cells in (pre)diabetic individuals [27–
37]. Insulin autoantibodies (IAA) are the ﬁrst to be detected
in children at risk for T1D and carry a high positive
predictive value for diabetes in siblings of T1D patients [14,
28]. However, autoantibodies and T cells have been detected
against autoantigens other than insulin in the human
[38].
T h ei m m u n ei m a g eo ft h eβ-cell is that of native com-
ponents of the β-cell membrane in their three-dimensional
conformation, as seen by B lymphocytes, and, more impor-
tantly, of fragments of intracellular β-cell proteins in the
form of 8–11 mer peptides loaded onto class I major
histocompatibilitycomplex(MHC)molecules,asseenonthe
β-cell surface by CD8+ T lymphocytes. In addition, profes-
sional antigen-presenting cells (APCs) present fragments of
autoantigens that are phagocytosed following the release of
subcellularβ-cellparticles or β-celldebrisin theextracellular
milieu and loaded onto MHC class I and class II molecules.
Given the key role of T lymphocytes in the T1D disease
process, the cartography of autoantigen-derived peptides
that are presented to class I-restricted CD8+ T cells and class
II-restricted CD4+ T cells, although still incomplete, will be
the main focus of this paper.
2.TCellRecognitionofInsulin
Both direct evidence in the mouse and indirect evidence in
the human point at insulin as a key autoantigen in T1D
autoimmunity. The search for T cell recognition of insulin
and the characterization of insulin epitopes recognized by
T lymphocytes along disease development is thus a major
challenge.
2.1. CD4+ T Cell Responses to Proinsulin. The study of T
cell responses to β-cell autoantigens have long been limited
to MHC class II-restricted responses but have faced major
methodological caveats, precluding translation into routine
laboratory procedures. CD4+ T cell responses to exogenous
insulin have ﬁrst been studied [39]. They have been shown
to be exacerbated in response to inhaled insulin in T1D
patients and in patients treated with insulin analogs, in
particular insulin detemir. They are beyond the scope of this
paper that will focus on T cell responses to insulin as part
of the autoimmune response to β-cells. Autoimmunity to
insulin seen in the rare insulin autoimmune syndrome in
patients with Grave’s disease will not be detailed either [39].
Following studies associating the detection of antibodies to
exogenous insulin to HLA-DR4, HLA-DR4-restricted T cell
responses have ﬁrst been prioritized. The characterization
of the high susceptibility DQ8 molecule led to the charac-
terization of DQ8-restricted responses in addition to DR4-
restricted responses.Clinical and Developmental Immunology 3
Proliferative T cell responses have been reported in the
human against both insulin and proinsulin, especially in
recent-onset T1D patients and prediabetic individuals [29–
31, 35] although also in nondiabetic subjects in some reports
[36, 40]. Despite treatment with insulin, long-standing T1D
patients were often found low responders [30, 31], as also
observed in case of CD8+ T cells [32]. An inverse correlation
has been observed between the presence of anti-insulin
autoantibodies and T cell responses to proinsulin [29, 30],
although not to insulin [40] and not in all studies [40, 41].
Somepatients showedaresponse toproinsulin,althoughnot
to insulin, indicating that C-peptide residues were among
the epitopes recognized [30]. Responses to insulin have been
observed in 25% of T1D patients and 10% of siblings in
a model in which proliferative responses were increased
in siblings of T1D patients, although not T1D patients
themselves, by addition of anti-DQ antibodies, implying the
presence of primed suppressive HLA-DQ-restricted T cell
responses to insulin in siblings [42].
Epitopes of proinsulin have been characterized in the
human [43](T ab le2). Using classIIknockout micethatwere
transgenic for the DQ8 diabetes susceptibility class II allele,
two immunodominant preproinsulin regions have been
deﬁned, spanning residues 1–24 and 44–63, respectively.
Immunodominant regions, that is, 14–33 and 74–93, were
diﬀerent in diabetes resistant transgenic mice that express
the diabetes resistant DQ6 allele [44]. Epitopes spanning
the C-peptide and A-chain junction have also been reported
as immunodominant in DR1∗0401 transgenic mice [45].
Using a preproinsulin peptide library, immunodominant
epitopes located within the C peptide (C13−29) and B chain
(B11−27) were preferentially recognized by CD4+ Tc e l l s
from autoantibody positive individuals at high risk for T1D
developmentwhereasCD4+ Tcellsfrominsulin-treatedT1D
patients were responsive to native insulin and insulin B
chain (B1−16). Unexpectedly, an IL-4 and IL-10 response
was predominant in both the naive CD45A and memory
CD45RO T cell compartments [36].
The role of the insulin B chain peptide B9−23 in
the NOD mouse led to test whether this peptide could
also be recognized in human T1D. Importantly, the three
dimensional structure of the DQ8 molecule complexed with
insulin peptide B9−23 has been determined [46]. Short-term
T cell lines obtained following a 7–10 day incubation of
peripheral blood mononuclear cells (PMBCs) from 10/12
recent-onset T1D patients, while not from controls, have
been shown highly proliferative to B9−23. Insulin B9−23-
speciﬁc T cell lines were restricted by HLA-DQ8 which
shows striking structural similarities with the NOD mouse
IAg7 class II molecule. Substantial numbers of interferon
γ-producing cells were detected in most recent-onset T1D
patients and prediabetic subjects using an ELISpot assay
[34]. However, the extent to which a B9−23 proliferative assay
can apply to routine evaluation in T1D remains elusive.
Presentation of peptide B9−23 was conﬁrmed in class II
knock out mice that were made transgenic for the human
DQ8 allele [47]. The characterization of peptides eluted
from HLA-DR4 class II molecules further allowed deﬁning
naturally processed proinsulin epitopes that clustered in
the C peptide and C peptide-A chain junction. Signiﬁcant
responses were observed against C13−32,C 19-A3 and C22-
A5. A positive interferon γ response to proinsulin peptides
was detected in 56% of 25 T1D patients and in none of 14
control subjects. By contrast, an IL-10 response to proinsulin
peptides was detected in one out of four control subjects
and T1D patients. An inverse correlation was observed
between the interferon γ and the IL-10 response to IA-2
and proinsulin peptides, although not to tetanus toxoid, in
patients and control subjects. Type 1 diabetic patients who
showed an IL-10 response were older at onset of diabetes
than patients who showed an interferon γ response [48].
In a diﬀerent set of experiments, expansion of T cells
from pancreatic draining lymph nodes of subjects with T1D
and controls allowed characterizing T cell clones. While T
cell clones from control individuals were highly polyclonal in
light of heterogeneous Vβ T cell receptor usage, around 50%
of T cell clones from 2 of 3 T1D patients expressed identical
Vβ chains, favoring an antigen-driven expansion of T cells.
Half of clonally expanded clones from the 2 patients were
speciﬁc for insulin A1−15. Both patients were HLA-DR401
which is strongly associated with susceptibility to T1D, but
also to insulin antibodies in insulin-treated patients. Both
patients, however, were long-standing T1D subjects who had
been treated with insulin for over than 10 years when lymph
node were collected. No response to insulin in blood, spleen
or pancreatic lymph nodes from a type 2 diabetic patient
treated with insulin was observed. It is hypothesized that T
cells residing in the pancreatic lymph nodes may persist in
individuals in whom β cells have been eliminated for years
[49]. The use of a human DR4B1∗0401-restricted CD4+
T cell clone that was obtained from a prediabetic, insulin
autoantibody-positive child further allowed showing that
posttranslational modiﬁcations of insulin epitopes impacts
on recognition by autoreactive T cells. The T cell clone was
speciﬁc for A1−13 and proliferated to human islet insulin,
indicating that the epitope was derived from native insulin.
The authors failed to obtain CD4+ T cell clones speciﬁc for
this epitope from two healthy donors. Recognition by the
A1−13-speciﬁc T cell clone was dependent on the formation
of a disulﬁde bond between adjacent cysteine residues A6
and A7 which, however, did not alter peptide binding to
HLA-DR4. The A6 and A7 cysteine residues were required
for T cell recognition by this clone, while the A11 cysteine
residue was not. Recognition of A1−13 was dependent on
the presence of oxidized residues that allowed formation
of a disulﬁde bond between residues A6 and A7 [50].
These data strengthen previous evidence that the oxidation
state of insulin-derived peptides plays a role in recognition
by insulin A1−14-speciﬁc T cells. Murine I-Ab and I-Ad-
restricted polyclonal T cells and T cell clones that were
speciﬁc for bovine A1−14 were shown to require reduction of
disulﬁde bonds for recognition [51]. Human DR1-restricted
T cell lines derived from insulin-treated patients were shown
to require intact disulﬁde bonds at A6 and A7 [52].
2.2. CD8+ T Cell Responses to Proinsulin. In human T1D, a
number of proinsulin epitopes that are presented by MHC4 Clinical and Developmental Immunology
Table 2: Class II-restricted∗ CD4+ T-cell epitopes on human preproinsulin.
§Epitope preproinsulin §Epitope Insulin nomenclature MHC restriction responders references
PPI1−24 L1−24 DQ8 Transgenic mice [44]
PPI11−26 L11-B2 DRB1∗0401 Transgenic mice [45]
PPI14−33 L14-B9 DQ6 Transgenic mice [44]
PPI20−36 L20-B12 DRB1∗0401 Transgenic mice [45]
PPI21−36 L21-B12 DR4 Transgenic mice [36, 45]
PPI33−47 B9−23 DQ8 At risk/recent-onsetTransgenic mice [35, 47]
PPI35−51 B11−27 DR16 At risk [36]
PPI44−63 B20-C7 DQ8 Transgenic mice [44]
PPI59−74 C3-C18 DR Human T cell lines [140]
PPI73−90 C17-A1 DR4 Transgenic mice [45]
PPI75−91 C19-A3 DR4 T1D [48]
PPI78−94 C22-A5 DR4 T1D [48]
PPI74−93 C19-A4 DQ6 Transgenic mice [44]
PPI70−93 C13-A6 DRB1∗0401 Transgenic mice [45]
PPI85−101 C29-A12 DRB1∗0401 Transgenic mice [45]
PPI69−88 C13−32 DR4 T1D [48]
PPI75−92 C19-A3 DR4 T1D [48]
PPI78−94 C22-A5 DR4 T1D [48]
PPI27−102 C29-A12 DR4 Transgenic mice [45]
PPI90−104 A1−15,A 1−13 DRB1∗0401 T cell clones [49, 51]
PPI90−102 Long-standing T1D
§The preproinsulin nomenclature here refers to the human preproinsulin sequence (errors in some publications have been corrected here, which explains
diﬀerences with cited references):
leader sequence: MALWMRLLPLLALLALWGPDPAAA;
B chain: FVNQHLCGSHLVEALYLVCGERGFFYTPKT;
C peptide: (RR)EAEDLQVGQVELGGGPGASGLQPLALEGSLQ(RR), (R) are excised during insulin processing;
A chain: GIVEQCCTSICSLYQLENYCN.
§§Epitopes for which class II-restriting alleles have not been deﬁned are not indicated in this table: PPI1−16 (L1−16), PPI5−20 (L5−20), PPI9−24 (L9−24), PPI,
L13-B4,L 17-B8,B 1−16,B 6–B22,B 16−32,B 25-C9,P P I 67−83,C 13−29 [36]; B1–B17,B 11–B27,B 20-C4,B 24-C4,B 30-C14,C 8–C24,C 18-A1,C 28-A11,A 6–A21 [141];
B10−25,B 25-C8,[ 140–142].
class I alleles have been characterized (Table 3). In a ﬁrst
study using peptide library-mediated in vitro assembly of
class I molecules, proinsulin peptides have been deﬁned
on the basis of their association with HLA-B8, A2, and
B15. Several epitopes harbor anchor residues that were only
weakly predicted or not predicted by common algorithms
or that did not contain canonical allele-speciﬁc binding
motifs [53]. Preproinsulin epitopes that carry C-terminal
residues that are generated by proteasome digestion in vitro
follow SYFPEITHI and BIMAS algorithm prediction and
bind in vitro to puriﬁed class II allele have been further
characterized [54–56]. In case of the common HLA-A∗0201
allele, immunogenicity in class I knock out A2.1 transgenic
mice has further been evidenced [54, 56]. However, self-
tolerance to mouse proinsulin epitopes is expected to
interferewithimmunogenicityofhumanproinsulinpeptides
in these mice. CTL that could be maintained in vitro after
restimulation were cytotoxic to A2.1 target cells, indicat-
ing that corresponding proinsulin epitopes were naturally
processed by cells expressing proinsulin. Further studies
characterized selected peptides within the proinsulin B-C
regionforrecognitionbyperipheralbloodmononuclearcells
from A1, A2, A3, A11, A24, B8, and B18 type 1 diabetic
patients [55] and peptides located within the preproinsulin
leader sequence [56, 57]. T cells speciﬁc for leader sequence
peptide15−24 wereshowncytotoxictohumanisletsexpressing
HLA-A∗0201, bringing further evidence that corresponding
T cells may participate to β-cell destruction along the human
disease process [57]. Leader sequence peptide14−23 has been
shown distinct from peptide15−24 [56], but peptide15−24 has
been eluted from HLA-A∗0201 molecules [57]. A majority
of T1D patients shows signiﬁcant responses to at least one
of the peptides covering the whole preproinsulin sequence,
while no response is usually observed in control individuals,
including type 2 diabetic patients who are treated with
exogenous insulin. There is no correlation between the
prevalence of responses to proinsulin peptides and the
aﬃnity levels of peptide binding to puriﬁed HLA class
I molecules. In many patients, responses are observed to
several peptides. However, the long preclinical phase that
precedes clinical diabetes does not preclude that a more
restricted set of peptides is recognized at initiation of the
autoimmune process. More surprisingly, proinsulin peptides
were recognized both in recent-onset and long-standing
diabetic patients [55, 56]. This may indicate that long-term
memory class I-restricted T cells persist in the long termClinical and Developmental Immunology 5
Table 3: CD8+ T-cell epitopes on human preproinsulin.
Epitope preproinsulin Epitope Insulin nomenclature MHC restriction responders references
PPI2−10 L2−10 HLA-A∗0201 Recent-onset T1D [96]
PPI2−11 L2−11 HLA-A∗0201 Recent-onset T1D [56]
PPI2−11 L2−11 HLA-A24 Recent-onset T1D [56]
PPI2−11 L2−11 HLA-B8 Recent-onset T1D [56]
PPI6−14/PPI6−16 L6−14/L6−16 HLA-A∗0201 Recent-onset T1D [56]
PPI14−23 L14−23 HLA-A∗0201 Recent-onset T1D [56]
PPI15−25 L14-B1 HLA-A∗0201 Recent-onset T1D [56]
PPI15−24 L15–L24 HLA-A∗0201 Recent-onset T1D [57]
PPI15−25 L14-B1 HLA-A∗0201 Transgenic mice [54]
PPI23−42 L23−18 HLA-A24 Recent-onset T1D [56]
PPI34−42 B10−18 HLA-A∗0201
Recent-onset T1D
[54, 55, 58] Islet graft rejection
Transgenic mice
PPI38−46 B14−22 HLA-A3 Recent-onset T1D [55]
PPI38−46 B14−22 HLA-A11 Recent-onset T1D [55]
PPI39−47 B15−23 HLA-A24 Recent-onset T1D [141]
PPI39−48 B15−24 HLA-A24 Recent-onset T1D [55]
PPI41−50 B17−26 HLA-A1 Recent-onset T1D [55]
PPI41−50 B17−26 HLA-A3 Recent-onset T1D [55]
PPI41−50 B17−26 HLA-A11 Recent-onset T1D [55]
PPI42−51 B18−27 HLA-A1 Recent-onset T1D [54, 55]
Transgenic mice
PPI42−51 B18−27 HLA-A∗0201 Recent-onset T1D [55]
PPI42−51 B18−27 HLA-B8 Recent-onset T1D [55]
PPI42−51 B18−27 HLA-B18 Recent-onset T1D [55]
PPI44−51 B20−27 HLA-A1 Recent-onset T1D [55]
PPI44−51 B20−27 HLA-B8 Recent-onset T1D [55]
PPI45−53 B21−29 HLA-A3 Recent-onset T1D [55]
PPI49−57 B25-C1 HLA-B8 Recent-onset T1D [55]
PPI51−61 B27-C5 HLA-B8 Recent-onset T1D [55]
PPI76−84 C20−28 HLA-A∗0201 Transgenic mice [54, 96]
Recent-onset T1D
PPI83−89 C27-C(34) HLA-A∗0201 Transgenic mice [54]
PPI85−94 C29-A5 HLA-A∗0201 Transgenic mice [54, 96]
Recent-onset T1D
PPI90−99 A1−10 HLA-A∗0201 Transgenic mice [54]
PPI101−109 A12−20 HLA-A∗0201 Transgenic mice [54, 96]
Recent-onset T1D
range in patients who have been deprived of residual β cells
for years. Long term persistence of memory CD8+ Tc e l l s
may explain the dramatic recurrence of T1D in recipients
of hemigrafts from monozygotic, diabetes-discordant twins
[15]. Reactivity to one of the B chain peptides identiﬁed,
preproinsulin33−47/B10−18, was shown to elicit a CD8+ Tc e l l
response in long-standing T1D patients who undergo islet
graft rejection using an ELISpot for granzyme, interferon
γ and IL-10 production and immunostaining with A2.1-
peptide tetramers [58]. In the NOD mouse in which no
T cell activation is seen in mice deprived of β-cells at
an early stage of the autoimmune process, full activation
of T cells is seen in the absence of residual β-cells once
the autoimmune process initiated [59]. The frequency of
preproinsulin-speciﬁc CD8+ T cells has been estimated,
using interferon γ ELISpot assays, at a median frequency
of 0.004% (range 0.0008–0.08%) of PMBCs [32]. In this
last study, they waned within 6 months after diabetes onset.
However, persistence of CD8+ T cell responses have been
observed in long-standing, insulin-treated T1D patients, in
particular to B chain peptides, as opposed to leader sequence
peptides [55, 56]. The combination of high sensitivity ﬂow6 Clinical and Developmental Immunology
cytometry detection and multiplex ﬂuorescent reagents [60]
is likely to allow high throughput CD8+ T cell analyses
complemented by functional studies in a near future.
3.TCellRecognitionofGAD,IA-2,andIGRP
While insulin can be deﬁned as a primary target of
the autoimmune response to β-cells in the NOD mouse,
direct evidence is lacking in the human. T cell recognition
of autoantigens other than insulin has been deﬁned in
the human. The lack of routine human T-cell assays is
due to intrinsic diﬃculties in measuring T-cell responses,
in particular in case of CD4+ T cells [61]. Circulating
antigen-speciﬁc T cells are present at a very low fre-
quency. Although these cells are sometimes detectable ex
vivo, their rarity challenges the sensitivity of technologies
such as enzyme-linked immunospot (ELISpot) and ﬂow
cytometry. Peptides that bind to HLA class II molecules
for presentation and recognition by T-cells have been more
diﬃcult to characterize in case of CD4+ than CD8+ T
cells, due to looser binding constraints in case of class II
than class I epitopes. Humanized mouse models expressing
human class I or class II HLA molecules have largely
been used to deﬁne class I-restricted and class II-restricted
epitopes.
3.1. CD4+ TC e l l s .Following the discovery of insulin as
an autoantigen in T1D, GAD was discovered as a second
autoantigen based on homologies of antigen precipitates
with the target of autoantibody in stiﬀ man syndrome. IA-
2 was then discovered in 1994. Autoantibodies detected
in recent-onset T1D patients recognize predominantly the
cytoplasmic domain of IA-2, which shares 80% sequence
homology with another tyrosine phosphatase, also known as
phogrin [62, 63]. Several approaches have been developed
to deﬁne CD4+ T cells in T1D. An extensive description
of epitopes recognized has been provided in a previous
review [43]. Increased proliferation of CD4+ T cells has
been reported in the presence of GAD extracted from pig
or human brain and islets [64, 65], overlapping peptides
covering the GAD65 and GAD67 sequences, in particular a
region covering residues 473–555, while other regions were
recognized by T cells from both T1D patients and controls
[66], recombinant GAD65 and GAD67 [67–69]i nu pt ot w o
thirdofpatientswithrecent-onsetorsubjectsatriskforT1D.
However, proliferative responses have also been observed in
normal individuals. An inverse relation between the detec-
tion of anti-GAD autoantibodies and proliferative responses
to GAD has been documented [69]. Proliferative responses
toaGADregionlocatedatpositions247–279hasbeencorre-
lated with responses to residues 32–47 of the coxsackie P2-C
viralsequence[70].Itisnoteworthythatthisregionislocated
outside of the human GAD65 region (GAD473−543) that was
shown to be immunodominant in T1D patients [66]. T cell
proliferative responses were also searched against selected
GAD peptides, such as GAD65506−518 which shows striking
homology with proinsulin24−36 [33, 71] or GAD65247−279,a
response that was correlated to T cell proliferative responses
to coxsackie viral peptide P2-C32−47 [70]. DQ-restricted
responses to recombinant GAD have further been deﬁned
in patients [42]. Several publications have since reported
proliferative responses of CD4+ T cells from T1D patients
or autoantibody-positive subjects at risk for T1D in the
presence of IA-2 or IA-2 peptides [40, 72]. Using IFN-
γ/IL-4 double-color ELISPOT, IA-2-speciﬁc, interferon γ-
secreting PMBCs were detected ex vivo in T1D patients
while not in controls [73]. A dominant IA-2805−820 epitope
in these studies was shown to share 56% identity with a
VP7 rotavirus protein [72]. However, diﬃculties to develop
reliableassaysinthesepioneeringstudieshavehamperedfur-
ther studies and may have explained variable outcomes, low
reproducibility of data, diﬃcult discrimination of responses
inT1Dpatientsandcontrolsandfailuretoestablishclinically
relevant assays. Standardization of conditions of antigen
presentation, restriction by class II HLA molecules and
proﬁlesofcytokinesproducedalongtheseassayswereusually
unknown in these studies.
The use of transgenic mice expressing functional MHC
class II molecules have been useful in helping to charac-
terize GAD and IA-2 class II epitopes. The ﬁrst class II
transgenic mice to be developed carried a DRB1∗0401 sus-
ceptibility allele. They led to identiﬁcation of two peptides,
selected among overlapping 20mer peptides as binding to
DRB1∗0401, as immunogenic and naturally processed by
DRB1∗0401-expressing mouse spleen cells, GAD65274−286
and GAD65115−127 [74]. Another study in DR4-transgenic
mice found that GAD65274−286 and GAD65115−127 and an
additional peptide, GAD65551−565, were immunodominant
[75]. GAD65551−565 was shown to be naturally processed
by using a combination of chromatography and mass
spectrometry of peptides bound by HLA-DR401 molecules
[76]. However, the class II susceptibility molecule that
confers the highest susceptibility in T1D is the HLA-
DQA1∗0301/DQB1∗0302 (DQ8) dimer. Humanized class
II mice devoid of endogenous mouse class II genes and
expressing DQ8 have been used to characterize autoanti-
gen epitopes presented by DQ8. GAD247−266 which shows
homology with coxsackie P2-C, and GAD509−528-speciﬁc,
DQ8-restricted Th1 CD4+ T cell lines were shown to
induce insulitis after adoptive transfer into DQ8-expressing
m i c et r e a t e dw i t hav e r yl o wd o s eo fs t r e p t o z o t o c i n
[77]. Notably, there are two amino acid diﬀerences in
GAD247−266 (GAD252 and GAD256) and one amino acid
diﬀerence in GAD509−528 (GAD509) between the murine
and the human sequence. A strong CD4+ Tc e l lr e s p o n s e
was observed and human GAD65 epitopes (GAD497−517,
GAD527−547,G A D 537−557) identiﬁed using a pool of 19 20–
23 mers overlapping peptides spanning two large regions
of GAD 65 in transgenic mice expressing DQ8 and back-
crossed onto the NOD background for two generations
[78].
Following identiﬁcation of GAD65551−565 as naturally
processed and as eliciting a T cell response in recent-onset
T1D patients and individuals at risks [73], soluble HLA-
DR401 or -DR404 TMrs complexed to GAD65551−565 were
used to analyze circulating T-cells from recent-onset T1D
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avidity CD4high tetramer-positive cells after expansion in
vitro and activation on speciﬁc plate-bound class II-peptide
monomers [79]. Seemingly, expansions were detected in
the presence of GAD65555−567 GAD65274−286 peptides, and
proinsulinB24−C36, using TMrs. [80]. Generating a panel
of GAD65-speciﬁc T cell lines from HLA-DR∗0301/∗0401
recent-onsetT1Dpatients,epitopeshavealsobeenidentiﬁed.
Two were presented by DR4-expressing APCs, one covering
amino acid residues 270–283, in close proximity, but outside
the homology region shared with Coxsackie virus P2-C
protein, a second covering residues 556–575, the peptide
largely overlapping with a 20 mer peptide having the highest
aﬃnity to DRB1∗0401 among known GAD65 peptides.
Both were characterized in two T1D patients carrying the
high susceptibility HLA-DR∗0401/DQB1∗0302 haplotype.
Two epitopes (GAD146−165 and GAD174−185)w e r ep r e s e n t e d
by APCs expressing the susceptibility HLA-DR∗1601 allele,
but one (GAD206−225) was presented by APCs expressing the
resistance allele HLA-DR∗1501 [81].
Among the many GAD epitopes characterized,
GAD555−567 has led to extensive studies, both ex vivo
and in transgenic mice. The transfer of a DR4-restricted
GAD555−567-speciﬁc CD4+ T cell clone induces insulitis in
Rag−/−I-Ab−/−B6 DR4 transgenic mice [82] while CD4+ T
cells carrying TCR transgenes from two distinct GAD555−567-
speciﬁc CD4 T cell clones in B6 DR4-transgenic mice
remained tolerant, although through diﬀerent mechanisms
[83]. An increase in the avidity of CD4+ T cell recognition of
GAD555−567 has been reported in three prediabetic subjects
along progression from autoantibody positivity to clinical
T1D [84].
In addition to studies of direct interactions of CD4+ T
cells and class II-restricted peptides, cellular binding assays
have been used for studying peptide-class II interactions for
a large number of DR and DQ molecules. A clustering of
peptides has been identiﬁed in the COOH-terminal region
of GAD and promiscuous peptides have been identiﬁed.
Most peptides were further shown to bind both diabetes-
predisposing and diabetes-protective class II molecules
[85–87] and DR as well as DQ molecules [88]. However,
limitations in these studies rely with the likelihood that, in
contrast with antiviral responses, peptides recognized along
the autoimmune response to β-cells cannot be predicted
on an aﬃnity basis [55, 56], many peptides showing
low to medium aﬃnity being recognized and inducing
immunogenic responses in humanized mice as recently
shown in a DQ8 NOD transgenic mouse [89].
Similar strategies have been followed to study CD4+ T
cellrecognitionofIA-2andIGRP.Usinglibrariesofsynthetic
peptides overlapping the intracytoplasmic domain of IA-2, a
dominant epitope recognized by DR4-restricted T cells from
subjects at risk for T1D has ﬁrst been identiﬁed, IA-2805−820,
which has 100% similarity with a sequence of the rotavirus
VP7 protein [90]. Studying a panel of naturally processed
islet epitopes by elution from APCs bearing HLA-DR4,
IA-2652−80,I A - 2 709−35,I A - 2 752−75,I A - 2 793−817,I A - 2 853−72,
IA-2955−76-speciﬁc CD4+ T cells have been identiﬁed as
proinﬂammatory T cells. Interestingly in this study, the
majority of nondiabetic, HLA-matched controls also showed
a response against islet peptides, but with the phenotype
proﬁle of IL-10-secreting T cells [48]. Two phogrin DQ8
epitopes (ICA512640−659 and ICA512755−776) previously
deﬁned as recognized by diabetogenic T cells in the NOD
mouse has been further identiﬁed using transgenic mice
expressing DQ8 on the NOD background [91]. The evidence
for molecular mimicry between an IA-2 (and GAD) epitope
and the rotavirus VP7 protein has been further detailed
by showing strong binding of both autoantigen and viral
peptides to HLA-DRB1∗04 and cross recognition by IA-2-
speciﬁc T cells [92]. The 831–860 region of IA-2 frequently
recognized by autoantibodies has been shown to be recog-
nized by IL-10-secreting T cells from T1D patients [93]. Fol-
lowing identiﬁcation of DRA1∗0101/DRB1∗0401-retricted
IGRP23−35 and IGRP247−259 and DRA1∗0101/DRB1∗0301-
retricted IGRP13−25 and IGRP226−238 epitopes, IGRP-speciﬁc
CD4+ T cells have been detected in more than 80% of
DRB1∗0401 or DRB1∗0301 healthy and T1D subjects [94].
Interestingly, autoantigen-speciﬁc CD4+ T cells have
been studied in very diﬀerent clinical settings, including
in autoantibody-positive individuals at risk for T1D, in
recent-onset T1D patients and in patients undergoing
pancreas/kidney as recently reported in 3 patients [95]o r
islet transplant [58]. Autoantibodies were detected either
pretransplant or reappeared 5 and 6 years posttransplant in
still normoglycemic patients, somewhat paralleling insulitis,
whatever the immunosuppression used. GAD-speciﬁc CD4+
T cells were detected using DRB1∗0405 and DRB4∗0101
TMrs and IGRP-speciﬁc CD8+ T - c e l l sw e r ed e t e c t e du s i n g
HLA-A2/A∗0201 class I pentamers along followup. Autore-
active T-cells are temporarily inhibited by immunosuppres-
sion, their reappearance is followed by further loss of insulin
secretion [95].
3.2. CD8+ TC e l l s .The ﬁrst evidence for the recognition of
GAD by A∗0201-restricted CD8+ T cells was obtained in one
asymptomatic and two recent diabetic patients. CD8+ Tc e l l s
detected in this study were shown to target HLA-A∗0201
peptide GAD114−123 and were cytotoxic to autologous
antigen-presenting cells incubated with the GAD114−123 pep-
tide or infected with a recombinant vaccinia virus expressing
GAD65 [38]. A list of epitopes along with class I-restricted
HLA molecule is provided in Table 4. The recognition of the
GAD114−123 epitope was conﬁrmed by another study using
an interferon γ Elispot assay [96]. Another peptide from IA-
2( I A - 2 797−805) was reported as the target of cytotoxic T cells,
but both in T1D patients and control individuals [97]. Using
algorithms to predict nonameric β-cell peptides that would
bind to the common HLA-A∗0201 allele and an interferon
γ Elispot assay, a human islet amyloid polypeptide (IAPP)
precursor protein, 6 out of 9 recent-onset T1D patients,
but none of longstanding T1D patients, were shown to
recognize preproIAPP peptide IAPP5−13[98]. Another IAPP
peptide (IAPP9−17) was deﬁned using the same approach
and an assay evaluating granzyme B secretion, along with
IGRP peptides IGRP215−223,I G R P 152−160,I G R P 228−236 and
IGRP266−273 glial ﬁbrillary acidic protein (GFAP) peptides
GFAP143−151and GFAP214−222,I A - 2 172−180,a n dI A - 2 482−490,8 Clinical and Developmental Immunology
Table 4: CD8+ T-cell epitopes of human T1D autoantigens (other than preproinsulin).
Epitope preproinsulin MHC restriction responders references
GAD114−123 HLA-A∗0201 Recent-onset T1D [38, 96, 103]
Transgenic mice
GAD114−122 HLA-A∗0201 Recent-onset T1D [101]
GAD110−118 HLA-A∗0201 Transgenic mice [103]
GAD159−167 HLA-A∗0201 Transgenic mice [103]
GAD476−484 HLA-A∗0201 Transgenic mice [103]
GAD536−545 HLA-A∗0201 Transgenic mice [103]
IAPP5−13 HLA-A∗0201 Recent-onset T1D [98]
IAPP9−17 HLA-A∗0201
At risk
[99, 100] Recent-onset T1D
T1D
IGRP215−223 HLA-A∗0201 Recent-onset T1D [100]
IGRP152−160 HLA-A∗0201 At risk [99, 100]
T1D
IGRP228−236 HLA-A∗0201 Transgenic mice [96, 102]
Recent-onset T1D
IGRP266−273 HLA-A∗0201 Transgenic mice [96, 102]
Recent-onset T1D
IGRP206−214 HLA-A∗0201 Transgenic mice [102]
IGRP337−345 HLA-A∗0201 Transgenic mice [102]
IGRP265−273 HLA-A∗0201 Transgenic mice [102]
GFAP143−151 HLA-A∗0201 At risk
[99]
T1D
GFAP214−222 HLA-A∗0201 At risk
[99]
T1D
IA-2797−805
Normal subjects
[97]
Recent-onset T1D
IA-2172−180 HLA-A∗0201 Recent-onset T1D [100]
IA-2482−490 HLA-A∗0201 Recent-onset T1D [100]
IA2790−798 HLA-A∗0201 Transgenic mice [103]
IA2805−813 HLA-A∗0201 Transgenic mice [103]
IA2830−839 HLA-A∗0201 Transgenic mice [103]
IA2962−970 HLA-A∗0201 Transgenic mice [103]
[95, 99, 100]. A strong inverse correlation between the
binding aﬃnity of β-cell peptides to HLA-A∗0201 and CTL
responses against those peptides was observed in recent-
onset type 1 diabetic patients. These data conﬁrmed that
many β-cell epitopes are recognized by CTLs in recent-
onset type 1 diabetic patients. Interestingly, IA-2 and GAD
have been deﬁned as a key autoantigen in T1D on the
basis of the predictive value of anti-IA2 and anti-GAD
autoantibodies in prediabetic individuals, while IGRP and
IAPP have not been deﬁned as key targets of autoantibodies
in T1D in the human. GAD114−122-speciﬁc CD8+ T cells, as
well as GAD-speciﬁc and insulin-speciﬁc CD4+ T cells, have
further been detected exclusively in T1D patients within the
memory CD45RO+ T cell population while na¨ ıve CD45RO
T cell stained with HLA-0201∗-GAD114−122 tetramers were
discriminative between control and T1D patients [101].
A combinatorial quantum dot MHC multimer technique
has further allowed detecting expansions of HLA-A∗0201-
restricted CD8+ T cells that were speciﬁc for IA-2797−805,
GAD65114−123,I G R P 265−273,a n dp r e p r o I A P P 5−13 in recent
onset diabetes patients, with a speciﬁcity ranging from 87%
to 100% and a sensitivity ranging from 25% to 40%, and in
islet transplantation recipients [60].
The use of HLA-A∗0201 transgenic mice has ﬁrst
reported or conﬁrmed the characterization of class I-rest-
ricted peptides that are potentially presented to CD8+ Tc e l l s
in the human. IGRP206−214,I G R P 337−345 and IGRP265−273
have been identiﬁed in HLA-A∗0201 transgenic mice on
the NOD genetic background and shown to be targeted by
pathogenic CD8+ T cells [102]. The systematic immuniza-
tion of HLA-A∗0201 transgenic mice using plasmids encod-
ing GAD65 or the catalytic unit of the intracellular domain
of IA-2 has allowed deﬁning 5 GAD peptides (GAD110−118,
GAD114−123,G A D 159−167,G A D 476−484,a n dG A D 536−545)
and 4 IA-2 peptides (IA2790−798,I A 2 805−813,I A 2 830−839,a n dClinical and Developmental Immunology 9
IA2962−970) that were recognized by CD8+ Tc e l l sf r o m
T1D patients, 3 of which (GAD114−123,G A D 536−545,a n d
IA2805−813) in more than 25% patients [103].
Shifts both in frequency and in immunodominance of
CD8+ T-cell responses have been observed within months
following T1D onset and were more rapid than changes in
autoantibody titers. Positive T-cell responses to islet epi-
topes (GAD65114−123, GAD65536−545,I G R P 228−236,P P I 2−10,
PPI34−42,P P I 42−51,a n dP I 101−109) observed at diagnosis were
shown to drop to non detectable levels, while newly targeted
epitopes were evidenced, in particular proinsulin B18−27,I A -
2206−214,a n dI G R P 265−273.H o w e v e r ,o fat o t a lo fp o s i t i v eT -
cell responses to islet epitopes observed at diagnosis, 26 of
42 dropped to nondetectable levels, while new epitopes were
targeted in only 5 [32].
3.3.RegulatoryTCells. Ther oleo fp r ot ecti v eCD4 + Tc ellsin
T1D has ﬁrst been deﬁned in the NOD mouse [104]. In the
human, initial reports documenting decreased numbers of
CD4+ Tr e g u l a t o r y( T reg) cells deﬁned as CD25+ [105]w e r e
not conﬁrmed by later works using more speciﬁc surface
phenotyping [106]. Few papers addressed the issue of Treg by
analyzing autoantigen-speciﬁc Treg. Despite the importance
of this question, the characterization of islet-speciﬁc Tregs
is still in its infancy, as it is rather diﬃcult to detect them
(their frequency being probably even lower than that of the
corresponding eﬀectors) and to expand them in vitro (most
of these cells being characterized by a state of anergy that
n e e d st ob er e v e r s e d ) .
The characterization of both proinﬂammatory (IFN-γ-
producing) and regulatory (IL-10-producing) CD4+ T-cell
responses against proinsulin and IA-2 indicate that Treg are
possibly key players. While T1D patients harbored predomi-
nant IFN-γ responses, healthy subjects were characterized by
higher frequencies of IL-10 responses speciﬁc for the same
epitopes. The same was not true for responses against an
irrelevant Ag such as tetanus toxoid. Moreover, T1D patients
displaying higher IL-10 responses were characterized by an
older age T1D onset, suggesting that these regulatory may
counterbalance autoimmune eﬀectors, at least transiently
[48]. IL-10-secreting CD4+ Treg speciﬁc for proinsulin and
IA-2 epitopes have been characterized as suppressive in vitro
in healthy subjects. This suppressive activity is however not
linked to IL-10 secretion, but rather to elimination of Ag-
presenting cells [107]. Importantly, we previously showed
that GAD-speciﬁc eﬀector CD4+ T cells cloned from T1D
patients could also be rendered anergic and suppressive
uponsustainedAg-speciﬁcinvitrostimulation[108].Similar
observations were made by showing that patients harboring
the protective I/III and III/III insulin VNTR haplotypes
displayed a threefold higher IL-10 release in proinsulin-
speciﬁc memory T cells. These data are consistent with
the hypothesis that VNTR-induced higher insulin levels
in the thymus promote Treg generation, oﬀering an addi-
tional explanation for the protective eﬀect of the VNTR
class III alleles [109]. Seemingly, cloned PPI70−90-speciﬁc
DRB1∗0401-restricted human T cells have been character-
ized as expressing a downregulatory T helper 2 phenotype
through predominant production of IL-5 and IL-10 and low
interferon γ production [110]. DRB1∗0401-restricted CD4+
TcellsthatarespeciﬁcforGAD65555−567 havebeenidentiﬁed
in normal individuals using GAD65-speciﬁc class II TMrs
after expansion in the presence of peptide, following removal
of CD4+CD25+Treg. Their expansion was reversed adding
back CD4+CD25+Treg [111, 112]. Taken together, these
observations suggest that detection of T-cell autoreactivity
should not be considered pathological per se, but should
rather be interpreted by functional proﬁling. Regulatory PI-
and GAD-speciﬁc T-cell clones can be obtained in vitro
under standard stimulating conditions in the absence of
any exogenous cytokines [113]. Similarly, GAD- and IGRP-
speciﬁc CD4+ Treg clones can be obtained by in vitro
stimulation of FoxP3-negative CD4+ T cells [114]. Whether
such clones are only generated in vitro or can also be isolated
ex vivo and their mechanism(s) of suppression remain
important questions for further investigation. On the same
line, there have been reports indicating that GAD-speciﬁc
circulating CD4+ T cells show an activation phenotype
that is not seen in control individuals, likely a memory
phenotype and are more prone to proliferate while less
dependent on CD28/B7-1 costimulation [115]. GAD65- and
proinsulin-speciﬁc T-cells, including cells that were spe-
ciﬁc for GAD106−125,G A D 526−545,G A D 266−285,G A D 556−575,
hPPI72−90 and hPPI94−110, have been shown to coexpress
CD25 and CD134 (OX40) as a distinctive feature when
compared to T cells from healthy subjects [116]. Beyond,
CD4+ T cells, polyclonal regulatory CD8+ T cells have
also been characterized. CD8+ CD45RA+ CD27− Tc e l l s
have been shown to control GAD65-speciﬁc CD4+ Tc e l l
expansions through a contact dependent mechanism and the
production of IL-10 [117].
4. Therapeutic Trials Using Peptides or
Autoantigensinthe Human
The characterization of T-cell epitopes is expected to help
developing T cell assays to be used in the followup of
immunotherapy trials in T1D, thus providing surrogate end
point markers of tolerance induction that may prove more
reliablethancurrentautoantibodyassays[118,119]andpave
the way towards antigen or peptide-speciﬁc immunotherapy.
4.1. Mechanisms of Tolerance. A major advantage of antigen
or peptide-speciﬁc immunotherapy over other forms of
immunotherapy in human autoimmune diseases is in focus-
ingtreatmentonself-reactiveTcellcloneswithoutimpairing
immune responses to unrelated antigens, especially tumoral
or infectious antigens. In T1D in particular, this may prove
of outmost importance considering that insulin therapy
has gained in eﬃcacy and safety over years, explaining the
progressively decreasing mortality gap between T1D patients
and the general population [120]. Although nonspeciﬁc
immune suppression has been shown partially eﬀective in
preserving β-cells from autoimmune destruction in recent-
onset T1D patients, immunosuppressive drugs used to
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that preclude their use in the long-term range. Peptide
and/or antigen-speciﬁc immunotherapy is thus likely to
allow optimal risk/beneﬁt ratio in T1D.
Immune tolerance is ensured in a succession of check-
points by a variety of mechanisms aﬀecting diﬀerentiating
lymphocytes in central lymphoid organs as well as mature
lymphocytes in the periphery. Tolerance in the periphery
rely on deletion of autoreactive cells, on ignorance of self
antigens, on active mechanisms that imprint an intrinsic
status on tolerant lymphocytes in the form of anergy or
immune deviation and on extrinsic mechanisms that involve
regulatory cells. Molecular interactions in the presentation
of autoantigen in the periphery are central to the tolerance
process and in strategies aiming at restoring or inducing
immune tolerance in autoimmunity. Elimination or repro-
gramming of deleterious autoreactive cells and activation
of regulatory cells to control autoimmune eﬀectors are the
major outcomes expected from antigen or peptide-speciﬁc
immunotherapy. These mechanisms have been clearly doc-
umented in preclinical models but are only starting to be
implemented in human studies.
Key advantages of inducing antigen-speciﬁc immune
tolerancehave been underscoredbut dependon mechanisms
of tolerance induction. First, it may not require knowing
the initiating target autoantigen, nor the ﬁne speciﬁcity of
T cells involved. Induction of regulatory T cells, whatever
their speciﬁcity, may induce bystander immunomodulation
within inﬂammatory sites, for instance, through in situ pro-
duction of protective cytokines, spreading of Th2 responses
or promoting tolerizing antigen presentation. Factors aﬀect-
ing the eﬃciency of antigen-based immunotherapy include
the size of the antigen used, the autoantigen expression
pattern,thestageofthediseaseprocessattimeofadminister-
ing the tolerizing autoantigen, the crypticity of the epitopes
presented, the autoantigen administration route and dose
[121].
Given the molecular constraints of T cell activation,
the induction of peptide-speciﬁc tolerance is expected to
require presentation of speciﬁc peptides to autoreactive
CD4+ T cells in a noninﬂammatory environment. Induction
of immune tolerance by injection of high doses of soluble
peptide or antigen or DNA vaccination has proven eﬃcient
in experimental models of autoimmunity, but concerns
have been raised by the risk of either exacerbating the
autoimmune process in some experimental conditions or
inducing anaphylactic reactions. The induction of tolerance
by the mucosal (oral or nasal) route has seemingly been
shown eﬃcient, mostly in preventing autoimmunity, in
preclinical models but has failed to apply to human diseases.
Mechanisms of action of the mucosal route diﬀer depending
on the dose of antigen delivered. The dose chosen in human
trials has so far been random. A promising approach to
induce tolerance in autoimmune diseases is intravenous
injection of antigen-coupled, ethylene carbodiimide-(ECDI-
) ﬁxed splenocytes. It has shown eﬃcient in animal models,
but is more complex to set up in the human. Among
mechanisms involved, both the induction of anergy, at
least in part through suboptimal costimulatory signaling,
and presentation of the tolerizing epitope by plasmacytoid
dendritic cells have been evidenced. As a last example,
altered peptide ligands (APLs), either antagonistic or partial
agonist APLs, have been successfully used in preclinical
models to prevent autoimmunity through anergy, immune
deviation or bystander suppression. As in case of soluble
peptide or antigen, the use of APLs has raised safety
issues relating with either exacerbation of autoimmunity
or anaphylactic reactions in the human in multiple scle-
rosis [122]. Deviation of autoimmunity to diﬀerent targets
is another danger that should not be excluded [1, 123,
124].
4.2. Insulin Trials. As a key autoantigen in T1D, insulin has
been used in several trials to downregulate the autoimmune
response in recent onset patients or to prevent the full
destruction of β-cells in prediabetic subjects. The ﬁrst trial
ever to modulate β-cell destruction used intravenous insulin
delivered by an external artiﬁcial pancreas to maintain
glycemic values between 3.3 and 4.4mmol/L during 14 days
at onset of T1D. This study in 12 T1D patients was compared
to conventional treatment using subcutaneous NPH insulin
injections (n = 14) and showed signiﬁcantly higher C-
peptide values in the experimental as compared to the
conventional group at one-year. Insulin doses in the exper-
imental group were in the order of 3U/kg/d. Mechanisms
may have involved β-cell rest as well immunomodulation
through intravenous delivery of insulin [125]. It is possible
that eﬃcient metabolic control rather than high insulin
doses explain the preservation of β cell function in this
study. In a comparable study in recent-onset T1D, the
nine patients who received high-dose intravenous insulin
infusion and the ten patients under intensive-therapy group
equally preserved β cell function along a one year follow-
up [126]. By contrast, in the DCCT study, intensive insulin
therapy allowed maintaining higher C-peptide levels than
conventional treatment with one or two injections a day
[127]. Fifteen years later, the ﬁrst randomized, double-
blind crossover study using nasal delivery of insulin in 38
prediabetic, autoantibody-positive individuals showed an
increase in anti-insulin antibodies and a decrease in T cell
proliferative responses to insulin, while no acceleration of
diabetes development and stable ﬁrst-phase insulin response
to glucose in the 26 individuals who did not develop diabetes
was observed at one year [128]. The Diabetes Prevention
Trial-Type 1 Diabetes Study [129] screened 84 228 ﬁrst
and second-degree relatives of T1D patients to select 3152
autoantibody-positive individuals and assigned 339 with a
projected ﬁve year risk over 50% to close observation or
low-dose subcutaneous ultralente insulin, 0.25U/kg/d plus
annual 4 day courses of continuous intravenous insulin
infusions with no delay in diabetes development after a
median followup of 3.7 years. In a group of individuals
with a ﬁve year projected risk of 26%–50%, no signiﬁ-
cant diﬀerence in the development of T1D was observed
between individuals randomly assigned to oral insulin versus
individuals assigned to placebo. However, in a subgroup
of individuals with anti-insulin autoantibodies ≥80nU/mL,
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compared to 10.4% of those receiving placebo (P<. 015),
suggesting that oral insulin should be tested speciﬁcally
in this subgroup of individuals [130]. However, a more
recent, double-blind, randomised, controlled study in 115
individuals receiving intranasal insulin (1 U/kg/d) versus
109 infants and siblings with ≥2 autoantibodies showed no
diﬀerence between the two groups [131]. It is even possible
in this study that nasal insulin had an accelerating eﬀect
on T1D development in individuals with ≥3 autoantibodies
against diﬀerent antigen speciﬁcities. These data face major
caveats. First, the dose of insulin delivered has little rationale.
Second, it is likely that prediabetes corresponds to fully
activated autoimmunity involving an already expanded T
cell repertoire. In new-onset T1D patients, oral delivery
of human insulin at doses ranging from 2.5 to 7.5mg/d
failed to show any beneﬁt on C-peptide secretion at one
year [132, 133]. Again, new-onset T1D is likely a late stage
hardly accessible to down regulation of the autoimmune
reaction. Administration of insulin B-chain in incomplete
Freund’s adjuvant has been shown to elicit strong B and
T cell immune responses to insulin in 12 subjects with
recent-onset T1D, but no C-peptide beneﬁt over a two-year
followup [134]. Finally, beyond the use of insulin as a key
autoantigen to downregulate the autoimmune response to
β-cells in prediabetes and in new-onset T1D, a key issue
remains whether or not immediate insulin therapy should
be started in noninsulin dependent diabetes patients who
are tested positive for islet cell autoantibodies, in particular
anti-GAD autoantibodies. Sixty anti-GAD positive patients
with a ﬁve year non-insulin dependent diabetes proﬁle
were randomized to either early insulin or sulfonylureas,
tested annually for C-peptide secretion under an oral
glucose tolerance test and followed up for 57 months. The
progression to insulin dependence was observed in 3 out
of 30 patients in the insulin group while in 13 of 30 in
the sulfonylurea group [135], in contrast with other studies
[136].
4.3. Glutamate Decarboxylase Trials. Following a dose-
ﬁnding study in patients with latent autoimmune diabetes
in adults indicating the safety of a primary injection and a
booster injection of 20μg each of recombinant human GAD
in a standard vaccine formulation with alum as adjuvant
[137],adouble-blindrandomisedstudywasperformedin35
GADautoantibody-positiveT1DpatientswhohadfastingC-
peptide levels >0.1nmol/L (0.3ng/mL) within 18 months of
diabetes diagnosis. Patients in the treated group received two
injections of GAD at 1 and 30 days of the study. The decrease
in fasting C-peptide values and stimulated secretion with
time was signiﬁcantly lower by 23% and 29%, respectively,
in treated versus placebo patients, 30 months after the
ﬁrst GAD injection. No adverse eﬀects were observed. An
increase in anti-GAD autoantibodies was seen in patients
who received GAD injections and peaked at 3 months of
the study. Interleukins 5, 10, 13, and 17, interferon-γ and
TNF-α production by T cells in response to GAD in vitro
were seen in treated patients, while not in the placebo group
[138].
4.4.HeatShockProteinTrials. Heatshockprotein60(hsp60)
has been discussed following NOD studies as an autoantigen
inT1DandTcellclonesspeciﬁcforhsp60peptidep277char-
acterized in this model. Several trials have been conducted
in the human using a 24-aminoacid peptide derived from
the C-terminus of human hsp60 in patients with established
T1D, including a trial in children with T1D. While no eﬀect
on C-peptide preservation was observed in the pediatric
study, one of the randomized study performed in 35 adult
T1Dpatientswithin<6monthsfollowingdiagnosisreported
signiﬁcant preservation of C-peptide values in the treated
group as opposed to signiﬁcant decrease in placebo-treated
patients. T-cell responses showed increased interferon γ and
decreased interleukin 13 production in response to hsp60
than to p277 and less interferon γ, more interleukin 10 and
13 in the treated group than in the placebo group [139].
5. Conclusion
Developing T-cell assays that allow characterizing diabetes
autoimmunity is a major challenge in human T1D. It is
expected to help deﬁning epitopes that are recognized in
T1D,topinpointkeyfunctionalfeaturesofepitope-speciﬁcT
lymphocytes along the natural history of the diabetes process
and to pave the way towards therapeutic strategies to induce
immune tolerance to β-cells. New T-cell technologies are
expected to allow deﬁning autoreactive T-cell diﬀerentiation
programsandcharacterizingautoimmuneresponsesincom-
parison to physiologically appropriate immune responses.
This may allow additional mechanistic studies and prove
instrumental in the discovery of immune correlates of eﬃ-
cacy in clinical trials, as initially reported using autoantibody
assays and now an open ﬁeld for T cell assays.
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